Type 2 diabetic hypertensive patients
Conditions
Interventions
To switch to the losartan 50 mg/HCTZ 12.5 mg drug combination from single use of lsartan 50 mg
To add the amlodipine 5 mg to basal use of Losartan 50 mg
Sponsors
Tokyo Women's Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria were (1) age > 20; (2) systolic blood pressure > 130 mmHg, or diastolic blood pressure > 80 mmHg; (3) patients who had already taken losartan for more than six months.
Exclusion criteria
Exclusion criteria: Exclusion criteria were (1) HbA1c > 8.0%; (2) the patients who had episodes of myocardial infarction or stroke within six months from the onset of this study; (3) heart failure; (4) past history of hyperuricemia, or uric acid level at baseline > 8.0 mg/dL; (5) kidney dysfunction (serum creatinine > 2.0 mg/dL); (6) secondary or malignant hypertension; or (7) kidney disease not caused by diabetic nephropathy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endpoints were blood pressure and glycemic control. We accessed the systolic and diastolic blood pressure level at two and four months. To evaluate glycemic control the HbA1c, fasting plasma glucose, and serum IRI values at two and four months. | — |
Countries
Japan
Contacts
Public ContactTetsuya Babazono
Tokyo Women's Medical University School of Medicine Diabetes Center
Outcome results
None listed